Introduction
It would seem intuitive that total prostate volume influences the probability of successfully biopsying a prostate tumor contained within the gland. This hypothesis is supported by studies demonstrating a negative correlation between total prostate volume and biopsy yield, 1, 2 and those where larger prostate volume was a predictor of positivity of a repeat biopsy as well as negativity of the initial biopsy. 3, 4 These findings have led to the suggestion that biopsy core number should be adjusted according to patient age and prostate volume to optimize sampling. 5 Mathematical models have also been constructed to advise on biopsy strategies for men with different ages and prostate volumes. [6] [7] [8] Such models are of use because a cumbersome study would be needed to assess the many different potential core numbers and location combinations with different prostate volumes.
5α-Reductase inhibitor treatment results in reductions in total prostate
volume, which could in theory enhance prostate cancer detection by reducing the benign component of the gland, thus increasing the likelihood of a biopsy core sampling tumor. This hypothesis was cast into sharp relief with the findings of the Prostate Cancer Prevention Trial (PCPT). 9 Over the course of the trial, prostate cancer prevalence was 24.8% lower in the finasteride versus the placebo arm, as detected in for-cause biopsies triggered by an abnormal PSA and/or digital rectal examination, or on a mandatory end-of-study biopsy.
However, tumors of Gleason grade 7-10 were significantly more common in the finasteride group than in the placebo group over the study duration, raising the concern that finasteride might promote the growth of more 4 aggressive tumors. However, an over-detection bias due to reductions in benign prostate volume has been hypothesized to account for the proportions of high-grade tumors. 10 The aim of the current study was to construct a mathematical model to predict the likelihood of a positive biopsy based on input variables of tumor volume, peripheral and transition zone volumes, and number of biopsy cores, to better inform the optimal biopsy protocol for a given subject. A secondary aim was to examine how the reduction in prostate volume observed with finasteride in the PCPT could alter detection of tumors, including those of high-Gleason grade.
Finally, the potential impact of this model on prostate cancer detection in the ongoing REduction by DUtasteride of prostate Cancer Events (REDUCE) trial, a chemoprevention study designed to determine if dutasteride 0.5 mg daily over 4 years reduces the risk of biopsy-detectable prostate cancer, 11 was examined, to understand how observations made from the PCPT may apply to the REDUCE study.
Materials and methods

Model construction
A mathematical model was constructed to analyze the effects of tumor size, peripheral zone (PZ) and transition zone (TZ) gland volumes, and the numbers of biopsy cores taken in the PZ and TZ, on prostate cancer detection. A key output of the model was the number of PZ and TZ cores needed to detect with probability ≥0.90 a specified tumor configuration of 4 nodules, the median number of tumor foci from previous data. 12 The total tumor volume represents the combined volume of all four nodules, with the second nodule half the size of the first, the third half the size of the second, and the fourth half the size of the third. For example, for a tumor volume of 3.00 cc, the nodules are of volume 1.59, 0.81, 0.39 and 0.21 cc respectively.
In common with other mathematical models for prostate cancer detection probability, a number of assumptions were used in the construction of the current model ( Table 1 volume. 13 The scenario where an equal reduction in tumor and prostate volume size occurred was therefore also modeled.
A further scenario explored the potential reduction in tumor volume needed to explain the observed difference in prostate cancer detection of 25% between the finasteride and placebo arms of the PCPT. In order to examine this scenario, two different methods were employed. Firstly, the probability of detecting a tumor of volume 1.5 cc in a prostate volume of 30 cc was derived for a sextant biopsy. This probability was then multiplied by 0.75 (representing a 25% reduction in detection probability) and the resulting probability used to determine the corresponding tumor volume. Secondly, the 'true' detection rate from the PCPT was calculated for the finasteride and placebo groups, assuming that the false negative rate was 18% for both treatment arms (an average figure based on the literature). 14, 15 Division of the detection rates from the PCPT by these calculated 'true' detection rates provided a detection probability, which was then applied to the model using average prostate volumes of 34 cc (placebo group) and 26 cc (finasteride group), the median prostate volumes at the end-of-study biopsy.
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Results
Minimum biopsy core number for cancer detection
The minimum number of PZ and TZ biopsy cores needed for ≥0.90 probability of cancer detection for a total tumor volume of 1.0 cc and 3.0 cc, by prostate volume, are shown in Table 2 . As would be expected, an increasing number of biopsies are required to ensure a probability of ≥0.90 as prostate volume Table 2 .
Modeling of the influence of prostate volume and tumor size reduction on prostate cancer detection If the assumption is adopted that tumor volume is reduced along with the gland volume by 25%, the increase in detection probability is less than if tumor volume is unchanged. For a 1.0 cc tumor and an initial prostate volume of 30 cc, the detection probability increases by 6% if tumor volume is also reduced by 25%, compared with a 17% increase if there is no change in tumor volume.
The potential reduction in combined low-and high-grade tumor volume needed to explain the observed difference in prostate cancer detection of 25% between the finasteride and placebo arms of the PCPT for prostate volume of 30 cc and tumor volume of 1.5 cc was also modeled. From the model, the corresponding detection probability is 0.90 for men treated with placebo. In the finasteride arm, overall cancer detection was reduced by 25%, resulting in a probability of 0.75 x 0.90 = 0.68. When the volume reduction of 25% is factored in, a reduction in tumor volume from 1.5 cc to 0.5 cc is required to reach this detection rate, suggesting that a twothirds reduction in tumor volume is required to produce a 25% reduction in detection rate. Using the second approach, and assuming an 18% false negative rate, the model estimated 'true' prostate cancer detection probabilities of 0.642 (placebo) and 0.557 (finasteride), corresponding to tumor sizes of 0.80 cc and 0.39 cc respectively, representing a 51% decrease in tumor volume. Table 4 
Discussion
In seeking to detect prostate cancer using transrectal ultrasound-guided prostate biopsy, a significant issue is the optimal choice of the number of cores to take in a biopsy session. Undersampling may result in clinically significant tumors being missed, while it has been argued that oversampling increases detection of clinically "insignificant" tumors, especially those associated with low PSA, thereby unnecessarily burdening the patient.
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To address the issue of the appropriate number of cores, Vashi et al. 8 have developed a mathematical probability model. They incorporated knowledge of tumor volumes considered "life-threatening", coupled with an estimation of doubling time, to recommend numbers of cores based on patient age and patient prostate volume. As would be expected, the recommended number of cores increases with prostate gland size, consistent with clinical study data. In the current model, this adjustment was not made directly; rather the user can examine probabilities by different tumor volumes, which can be adjusted to account for age. Despite these differences in modeling approach there is strong consistency between the results.
Comparisons with data from clinical practice studies are problematic, as to our knowledge, no study has systematically compared different numbers of biopsy cores against saturation biopsy techniques, or indeed biopsies from radical prostatectomy specimens. Therefore, while almost all studies have demonstrated that more cores tend to result in higher detection rates, such studies are not able to determine the optimal approach, as tumor prevalences, rather than detection rates, remain unknown. The "Vienna nomogram" was also constructed to provide guidance on biopsy core number, but based on clinical rather than modeled data. 5 Although the use of the nomogram resulted in a 66.4% higher prostate cancer diagnosis rate compared with a control arm using octant biopsy, it has not been determined whether the nomogram was Furthermore, if 5α-reductase inhibitors reduce tumor volume, as well as benign epithelial volume, the detection bias could also be further reduced.
One inevitable conclusion from the PCPT is that finasteride had a greater effect on low-versus high-grade tumors. Therefore, it can be hypothesized that finasteride decreased serum PSA less in high-grade tumors compared with low-grade tumors. Because PSA was doubled in the finasteride group, and a PSA >4 ng/mL was used to trigger for-cause biopsies, a lesser effect of finasteride on high-grade tumors would lead to a greater likelihood of biopsy.
Therefore it is likely that the increased detection of high-grade tumors in the finasteride arm of the PCPT was due in part to the effect of volume reductions on tumor detection, and also to the utility of PSA as an indicator of high-grade cancer.
Another important observation from the PCPT data using this model is the Table 1 .
• The ratio of peripheral zone (PZ) to transitional zone (TZ) volume is 3:1
• The number of tumor nodules is specified as 4: the median number of tumor foci from previous data 12 • The sum of tumor nodules represents the overall tumor volume o The dominant nodule is in the PZ with probability 0.80 18, 19 o The second dominant nodule is in the TZ with probability 0.20 20 o The probability of no tumor nodules in the TZ is 0.40
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• The probability of the 4 tumor nodules being distributed in the PZ and TZ was chosen as follows: volumes of the 4 nodules (based on the nodule volumes outlined in Table 1 ), and put K P for the number of cores in the PZ, K T for the number of cores in the TZ, V P for the volume of the PZ, and V T for the volume of the TZ. The detection probabilities (P 1 , P 2 , P 3 , P 4 ) are then: where the probability of detection of each of the 4 nodules is multiplied by the probability of each nodule being distributed in the PZ and TZ as outlined in Table 2 .
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